Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 453-140-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: theoretical approach
- Adequacy of study:
- key study
- Study period:
- 19 Jan 2005
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP assessment report based on expert judgement.
- Objective of study:
- other: toxicokinetic assessment
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- An expert assessment was made based on all data available.
- GLP compliance:
- no
- Species:
- other: none
- Route of administration:
- other: oral, dermal and inhalation
- Vehicle:
- other: not applicable
- Details on study design:
- A toxicokinetic assessment has been performed based on available physico-chemical properties and toxicological data of the substance.
- Conclusions:
- The substance is considered to have low bioaccumulation potential based on its log Pow.
The oral absorption is expected to be low. Uptake via inhalation is not anticipated. The substance will to some extent be dermally absorbed.
Reference
The acute oral and dermal toxicity of DHX2 is low, with the LD50 being higher than 2000 mg/kg bw in both cases. The 28 -day toxicity study also revealed that DHX2 has a low toxicity with a NOAEL of 1000 mg/kg bw/day. Therefore, an extensive toxicokinetic assessment is considered of limited value. Below, an assessment of the anticipated toxicokinetic behaviour of DHX2 is given.
Absorption
The water solubility of DHX2 is high (>1000 g/L). Under physiological conditions, the compound will be completely ionised. Since the water solubility of DHX2 is high and the log Pow is relatively low (1.43), it is unlikely that non-dissociated DHX2 will be absorbed to a high extent from the gastro-intestinal tract. Therefore, it is to be expected that the oral bioavailability, and thus the systemic exposure, of non-dissociated DHX2 will be low (1).
Uptake via inhalation is not anticipated because the vapour pressure measured is that of the water part of the substance and the vapour pressure of the organic part of the substance is not expected to be significant as the organic part of the substance is a salt and has a molecular weight of 576.
Since the bioavailability fo dermally applied compounds can be assumed to be zero for substances with a log Pow below -1 and 5 or a relative molecular mass over 700 (2), it is to be expected that DHX2 will to some extent be absorbed through the skin.
Distribution
Once DHX2 is absorbed, it will probably be distributed throughout extracellular body water. It will not be distributed into peripheral tissue. The compound will hardly bind to plasma proteins because of its high polarity.
Metabolism and excretion
In case absorption occurs, the primary and tertiary amines may undergo conjugation, most probably by acetylation or glucuronidation (3). The carboxy groups will be rapidly conjugated by glucuronidases and/or sulfatases.
Because of the high water solubility, the unchanged compound will be excreted extensively via the kidneys. The hydroxylated and conjugated metabolites will be excreted via urine or bile.
The very rapid metabolism and excretion will probably result in a relatively short elimination half-life of DHX2.
Based on the expected kinetic behaviour in the body, as described above, DHX2 will not accumulate in the body after prolonged exposure.
References
1. L.S. Schanker etal. Absorption of drugs from the rat small intestine. J. Pharmacol. Exp. Ther. 123 (1958) pp 81 -88.
2. T.G. Vermeire etal., Estimation of consumer exposure to chemicals: application of simple models. The Science of the Total Environment 136 (1993) 155 -176.
3. A. Parkinson. In: Casarett and Doull's Toxicology, The basic science of poisons, fifth edition. Ed. C.D. Klaassen. Chapter 6: Biotransformation of xenobiotics. McGraw-Hill, New York (2001).
Description of key information
An expert assessment was made based on all data available.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
The acute oral and dermal toxicity of DHX2 is low, with the LD50 being higher than 2000 mg/kg bw in both cases. The 28 -day toxicity study also revealed that DHX2 has a low toxicity with a NOAEL of 1000 mg/kg bw/day. Therefore, an extensive toxicokinetic assessment is considered of limited value. Below, an assessment of the anticipated toxicokinetic behaviour of DHX2 is given.
Absorption
The water solubility of DHX2 is high (>1000 g/L). Under physiological conditions, the compound will be completely ionised. Since the water solubility of DHX2 is high and the log Pow is relatively low (1.43), it is unlikely that non-dissociated DHX2 will be absorbed to a high extent from the gastro-intestinal tract. Therefore, it is to be expected that the oral bioavailability, and thus the systemic exposure, of non-dissociated DHX2 will be low (1).
Uptake via inhalation is not anticipated becausethe vapour pressure measured is that of the water part of the substance and the vapour pressure of the organic part of the substance is not expected to be significant as the organic part of the substance is a salt and has a molecular weight of 576.
Since the bioavailability fo dermally applied compounds can be assumed to be zero for substances with a log Pow below -1 and 5 or a relative molecular mass over 700 (2), it is to be expected that DHX2 will to some extent be absorbed through the skin.
Distribution
Once DHX2 is absorbed, it will probably be distributed throughout extracellular body water. It will not be distributed into peripheral tissue. The compound will hardly bind to plasma proteins because of its high polarity.
Metabolism and excretion
In case absorption occurs, the primary and tertiary amines may undergo conjugation, most probably by acetylation or glucuronidation (3). The carboxy groups will be rapidly conjugated by glucuronidases and/or sulfatases.
Because of the high water solubility, the unchanged compound will be excreted extensively via the kidneys. The hydroxylated and conjugated metabolites will be excreted via urine or bile.
The very rapid metabolism and excretion will probably result in a relatively short elimination half-life of DHX2.
Based on the expected kinetic behaviour in the body, as described above, DHX2 will not accumulate in the body after prolonged exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.